Abivax (AAVXF) Total Liabilities (2021 - 2026)

Abivax has reported Total Liabilities for 6 years, with the latest figure at $137.6 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 22.11% year-over-year to $137.6 million in Q1 2026; TTM through Mar 2026 was $137.6 million, a 22.11% decrease from a year earlier, with the FY2025 full-year figure at $150.3 million, down 14.56% from the prior year.
• Total Liabilities was $137.6 million for Q1 2026 at Abivax, down from $150.3 million in the prior quarter.
• The five-year high for Total Liabilities was $181.2 million in Q2 2025, with the low at $66.6 million in Q4 2022.
• Average Total Liabilities over 5 years is $148.4 million, with a median of $150.3 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities slipped 27.36% in 2022, then surged 100.77% in 2023.
• Over 5 years, Total Liabilities stood at $66.6 million in 2022, then soared by 100.77% to $133.7 million in 2023, then jumped by 31.55% to $175.9 million in 2024, then decreased by 14.56% to $150.3 million in 2025, then slipped by 8.46% to $137.6 million in 2026.
• The last three Total Liabilities figures came in at $137.6 million (Q1 2026), $150.3 million (Q4 2025), and $143.4 million (Q3 2025), per Business Quant data.